{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:59:18Z","timestamp":1760551158041,"version":"build-2065373602"},"reference-count":18,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Botulinum toxin A (BoNT-A) is a potent protein that can selectively modulate neurotransmission from nerve endings, resulting in the blocking of neurotransmitter releases and causing muscular paralysis [...]<\/jats:p>","DOI":"10.3390\/toxins12060394","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:50:49Z","timestamp":1592268649000},"page":"394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4771","authenticated-orcid":false,"given":"Hann-Chorng","family":"Kuo","sequence":"first","affiliation":[{"name":"Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, and Tzu Chi University, Hualien 970, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lin, Y.H., Chiang, B.J., and Liao, C.H. (2020). Mechanism of action of botulinum toxin A in treatment of functional urological disorders. Toxins, 12.","DOI":"10.3390\/toxins12020129"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Jiang, Y.H., and Kuo, H.C. (2020). The pharmacological mechanism of diabetes mellitus-associated overactive bladder and its treatment with botulinum toxin A. Toxins, 12.","DOI":"10.3390\/toxins12030186"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wang, C.C., Lee, C.L., and Kuo, H.C. (2016). Efficacy and safety of intravesical onabotulinumtoxinA injection in patients with detrusor hyperactivity and impaired contractility. Toxins, 8.","DOI":"10.3390\/toxins8030082"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liao, C.H., Wang, C.C., and Jiang, Y.H. (2016). Intravesical onabotulinumtoxinA injection for overactive bladder patients with frailty, medical comorbidities or prior lower urinary tract surgery. Toxins, 8.","DOI":"10.3390\/toxins8040091"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, P.Y., Lee, W.C., Wang, H.J., and Chuang, Y.C. (2020). Therapeutic efficacy of onabotulinumtoxinA delivered using various approaches in sensory bladder disorder. Toxins, 12.","DOI":"10.3390\/toxins12020075"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Jiang, Y.H., Yu, W.R., and Kuo, H.C. (2020). Therapeutic effect of botulinum toxin A on sensory bladder disorders\u2014from bench to bedside. Toxins, 12.","DOI":"10.3390\/toxins12030166"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lo, C.W., Wu, M.Y., Yang, S.S.D., Jaw, F.S., and Chang, S.J. (2020). Comparing the efficacy of onabotulinumtoxinA, sacral neuromodulation, and peripheral tibial nerve stimulation as third line treatment for the management of overactive bladder symptoms in adults: Systematic review and network meta-analysis. Toxins, 12.","DOI":"10.3390\/toxins12020128"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Yeh, T.C., Chen, P.C., Su, Y.R., and Kuo, H.C. (2020). Effect of botulinum toxin A on bladder pain\u2014molecular evidence and animal studies. Toxins, 12.","DOI":"10.3390\/toxins12020098"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Jhang, J.F. (2019). Using botulinum toxin A for treatment of interstitial cystitis\/bladder pain syndrome\u2014possible pathomechanisms and practical issues. Toxins, 11.","DOI":"10.3390\/toxins11110641"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, H.J., Yu, W.R., Ong, H.L., and Kuo, H.C. (2019). Predictive factors for a satisfactory treatment outcome with intravesical botulinum toxin A injection in patients with interstitial cystitis\/bladder pain syndrome. Toxins, 11.","DOI":"10.3390\/toxins11110676"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kuo, Y.C., and Kuo, H.C. (2016). Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis\u2014different mechanisms of action of botox on bladder dysfunction?. Toxins, 8.","DOI":"10.3390\/toxins8030075"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chen, C.L., and Meng, E. (2020). Can botulinum toxin A play a role in treatment of chronic pelvic pain syndrome in female patients?\u2014Clinical and animal evidence. Toxins, 12.","DOI":"10.3390\/toxins12020110"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kao, Y.L., Huang, K.H., Kuo, H.C., and Ou, Y.C. (2019). The therapeutic effects and pathophysiology of botulinum toxin A on voiding dysfunction due to urethral sphincter dysfunction. Toxins, 11.","DOI":"10.3390\/toxins11120728"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lee, Y.K., and Kuo, H.C. (2019). Therapeutic effects of botulinum toxin A, via urethral sphincter injection on voiding dysfunction due to different bladder and urethral sphincter dysfunctions. Toxins, 11.","DOI":"10.3390\/toxins11090487"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chen, C.H., Tyagi, P., and Chuang, Y.C. (2019). Promise and the pharmacological mechanism of botulinum toxin A in chronic prostatitis syndrome. Toxins, 11.","DOI":"10.3390\/toxins11100586"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Hsu, Y.C., Wang, H.J., and Chuang, Y.C. (2016). Intraprostatic botulinum neurotoxin type A injection for benign prostatic hyperplasia\u2014A spotlight in reality. Toxins, 8.","DOI":"10.3390\/toxins8050126"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chiang, B.J., Kuo, H.C., and Liao, C.H. (2019). Can botulinum toxin A still have a role in treatment of lower urinary tract symptoms\/benign prostatic hyperplasia through inhibition of chronic prostatic inflammation?. Toxins, 11.","DOI":"10.3390\/toxins11090547"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chang, Y.H., Hsiao, P.J., Huang, C.P., Wu, H.C., Hsieh, P.F., and Chou, E.C.L. (2020). A Comparative observational study to evaluate the efficacy of mid-urethral sling with botulinum toxin A injection in urinary incontinence patients. Toxins, 12.","DOI":"10.3390\/toxins12060365"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/6\/394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:38:47Z","timestamp":1760175527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/6\/394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,14]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["toxins12060394"],"URL":"https:\/\/doi.org\/10.3390\/toxins12060394","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2020,6,14]]}}}